New Higher Dose of Wegov (Semaglutide 7.2 mg): FDA Approval, Side Effects, and Dosing Guidance
- Joshua Silva, MD
- Mar 23
- 3 min read
Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD, serving patients across Utah
The FDA has approved a higher dose of semaglutide (Wegovy®) up to 7.2 mg weekly for weight loss. Higher doses can lead to greater weight loss, but also increase the risk of side effects—especially gastrointestinal symptoms and dysesthesia (tingling or skin sensitivity). There is currently no standardized guideline for how to safely increase to this dose. ¹,²
What Is the New Wegovy Dose (7.2 mg) and What Changed?
The new FDA-approved maximum dose of Wegovy is 7.2 mg weekly, increased from the previous limit of 2.4 mg weekly.¹
With this update:
Patients may now be treated up to 7.2 mg weekly
This is a 3× higher maximum dose
The goal is additional weight loss in patients who tolerate lower doses¹
Does a Higher Dose of Wegovy Lead to More Weight Loss?
Yes. Higher-dose semaglutide (7.2 mg weekly) leads to greater average weight loss than 2.4 mg in clinical trials.²
~18.7% weight loss with 7.2 mg
~15.6% with 2.4 mg
Up to ~20.7% in patients who remained on treatment
Higher doses also increased the likelihood of achieving ≥25% total body weight loss.²
However, side effects increase with dose, including gastrointestinal symptoms and dysesthesia.¹,²
Wegovy 7.2 mg Side Effects: What’s Different at Higher Doses?
Higher doses of Wegovy increase the risk of dose-dependent side effects, including gastrointestinal symptoms and newer effects like dysesthesia.¹,²
Common (Dose-Dependent)
Nausea
Vomiting
Constipation or diarrhea
Bloating / early fullness
More Noticeable at Higher Doses
Reflux and indigestion
Fatigue
Dehydration risk
Newer / Less Common but Important
Dysesthesia (altered skin sensation such as tingling, burning, or sensitivity)
Tingling, burning, or skin sensitivity
More common at higher doses
More commonly reported at higher doses compared to standard dosing.¹
How Do You Increase Wegovy to 7.2 mg Safely? (No Official Guidelines Yet)
👉 There is currently no official, standardized titration protocol for increasing from 2.4 mg to 7.2 mg.¹
This means:
No defined stepwise dosing schedule
No widely accepted clinical pathway
Limited real-world experience so far
In practice, most clinicians are taking a cautious, gradual approach, increasing the dose in smaller increments and monitoring for side effects before advancing.
Who Should Consider a Higher Wegovy Dose (7.2 mg)?
Higher doses may be considered for patients who tolerate current dosing well but need additional weight loss.
Not required for success
Consider if:
You tolerate your current dose well
Weight loss has slowed or plateaued
Dose increases should be:
Gradual
Closely monitored
Individualized
In practice, clinicians often:
Increase in small increments
Allow time between changes
Prioritize tolerability over speed
Bottom Line: Is the 7.2 mg Wegovy Dose Right for You?
The 7.2 mg Wegovy dose offers greater weight loss potential, but with higher risk of side effects and no clear dosing roadmap.¹,²
✅ More weight loss potential
⚠️ Higher risk of side effects (including dysesthesia)
❗ No standardized way to increase to this dose
Careful, individualized dosing is the safest approach.
Disclaimer
This article is for educational purposes only and is not a substitute for medical advice.
About the Author
Dr. Joshua Silva, MD, is a licensed physician and Medical Director of Potere Health MD. He earned his medical degree from the University of Hawaiʻi John A. Burns School of Medicine and completed residency training in Occupational and Environmental Medicine at the University of Utah, where he also earned a master’s degree in Occupational Health. He later completed a Master of Business Administration with an emphasis in health care administration at Ohio University.
Dr. Silva is the Medical Director of Potere Health MD and specializes in up to date, evidence-based weight management, including GLP-1 and GIP therapies such as semaglutide and tirzepatide. He provides in-person and virtual care for patients throughout Utah.
Sources:
U.S. Food and Drug Administration. FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide. Published March 19, 2026. Accessed March 23, 2026.
Wharton S, Freitas P, Hjelmesæth J, et al; STEP UP Trial Investigators. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomized, controlled, phase 3b trial. Lancet Diabetes Endocrinol.2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8.
Comments